Rituximab treatment for thrombotic thrombocytopenic purpura associated with human immunodeficiency virus failing extensive treatment with plasma exchange: A report of two cases

AIDS Patient Care and STDs

Volumn 24, Issue 6, 2010, Pages 349-352

  Evans, Michael W ^a   Vaughan, Leroy B ^a   Giffi, Victoria S ^a   Zimrin, Ann B ^a   Hess, John R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LACTATE DEHYDROGENASE; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; PLASMAPHERESIS; REMISSION; SCHISTOSOMA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; TREATMENT RESPONSE; COMPLICATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 77954202691     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2009.0313     Document Type: Article

References (19)

1. George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006;354:1927-1935.
2. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med 1998;339:1578-1584. (Pubitemid 28536132)
3. Bejamin M, Terrell DR, Vesely SK, et al. Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clin Infect Dis 2009; 48:1129-1137.
4. Moore RD. Schistocytosis and a thrombotic microangiopathy- like syndrome in hospitalized HIV-infected patients. Am J Hematol 1999;60:116-120.
5. Stefanescue R, Bassett D, Modarresi R, Santiago F, Fakruddin M, Laurence J. Synergistic interactions between interferon-g and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosis. Blood 2008;112:340-349.
6. Laurence, J, Mitra D, Steiner M, Staiano-Coico L, Jaffe E. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells. Blood 1996;87:3245-3254.
7. Maryland Department of Health and Mental Hygiene. Baltimore City HIV/AIDS Epidemiological Profile. Fourth Quarter, 2008. www.dhmh.state.md.us/AIDS/ Data&Statistics/BaltimoreCityHIVEpiProfile122008.pdf (Last accessed January 19, 2009).
8. Gervason C, Ridolfo AL, Vaccarezza M, et al. Thrombotic Microangiopathy in Patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. Clin Infect Dis 2002;35:1534-1540.
9. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JAK, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005;3:1432-1436.
10. Novitzky N, Thomas J, Abrahams L, du Toit C, McDonald A. Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy. Br J Hematol 2005;128:373-379.
11. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIVassociated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005;106:1538-1543.
12. Bower M, Veraitch O, Szydlo R, et al. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood 2009;113:4521-4524.
13. Mounzer K, DiNardo A, Goldstein K. Thrombotic thrombocytopenic purpura during immune reconstitution. AIDS 2007;21:2559-2560.
14. Coppo P, Adrie C, Azoulay E, et al. Infectious diseases as a trigger in thrombotic microangiopathies in intensive care unit (ICU) patients? Intens Care Med 2003;29:564-569.
15. Meir EB, Amital H, Levy Y, et al. Mycoplasma-pneumoniaeinduced thrombotic thrombocytopenic purpura. Acta Haematol 2000;103:112-115.
16. Chang JC, Shopstone A, Llenado-Lee MA. Postoperative thrombotic thrombocytopenic purpura following cardiovascular surgeries. Am J Hematol 1996;53:11-17.
17. Muniz AE, Barbee RW. Thrombotic thrombocytopenic purpura (TTP) presenting as pancreatitis. J Emerg Med 2003; 24:407-411.
18. Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 2010;91:1-19.
19. Howard MA, Williams LA, Terrel DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, III: An additional study of 57 consecutive patients, 2002-2005. Transfusion 2006;46:154-156.